PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 6505 (115th)

Medicare Negotiation and Competitive Licensing Act of 2018

referredUnited States· United States Congress· EN

Introduced

25 July 2018

Last action

3 August 2018 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Doggett, Lloyd [D-TX-37], Sen. Welch, Peter [D-VT], ELIJAH CUMMINGS, Rep. Khanna, Ro [D-CA-17], Rosa DeLauro, Rep. Schakowsky, Janice D. [D-IL-9], Marcy Kaptur, Rep. Pocan, Mark [D-WI-2], Raúl Grijalva, Alma Adams, Rep. Barragán, Nanette Diaz [D-CA-44], Karen Bass, Rep. Beatty, Joyce [D-OH-3], Earl Blumenauer, Rep. Bonamici, Suzanne [D-OR-1], Matt Cartwright, Rep. Castro, Joaquin [D-TX-20], Rep. Chu, Judy [D-CA-28], David Cicilline, Rep. Clarke, Yvette D. [D-NY-9], Emanuel Cleaver, Rep. Cohen, Steve [D-TN-9], Charlie Crist, PETER DEFAZIO, Rep. DeSaulnier, Mark [D-CA-10], Keith Ellison, Dwight Evans, Rep. Garamendi, John [D-CA-8], Vicente Gonzalez, Al Green, LUIS GUTIERREZ, Colleen Hanabusa, ALCEE HASTINGS, Brian Higgins, Sheila Jackson Lee, Rep. Jayapal, Pramila [D-WA-7], EDDIE JOHNSON, Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. Krishnamoorthi, Raja [D-IL-8], JAMES LANGEVIN, Al Lawson, Barbara Lee, SANDER LEVIN, JOHN LEWIS, Alan Lowenthal, Michelle Lujan Grisham, CAROLYN MALONEY, Betty McCollum

Subjects

Healthcare

Source updated

11 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Medicare Negotiation and Competitive Licensing Act of 2018 This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.) The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities. Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 25 July 2018

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 25 July 2018

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 25 July 2018

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 27 July 2018

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  5. 3 August 2018

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

Sponsors

Showing 48 of 107 sponsors and actors.

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.